ASCO invited its members to submit questions about issues and challenges they see emerging while caring for individuals with cancer in the context of the coronavirus pandemic. Currently, limited clinical cancer-specific data are available and information is evolving. The following information is based on evidence gathered through a PubMed searches of the medical literature, a search of relevant websites with information on infectious diseases (CDC, WHO, IDSA, etc.), and input provided by clinical oncologists and infectious disease experts. ASCO will update this information as new questions emerge and evidence develops.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company is working with the U.S. Food & Drug Administration (FDA) to initiate a randomized, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), to evaluate the safety and efficacy of Actemra® (tocilizumab) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care.
Helicobacter pylori infection and a family history of gastric cancer are the main risk factors for gastric cancer. Whether treatment to eradicate H. pylori can reduce the risk of gastric cancer in persons with a family history of gastric cancer in first-degree relatives is unknown.
Incidence of early-onset gastric cancer that is clinically and genetically distinct from late-onset disease has increased steadily in the United States, an “alarming phenomenon” that warrants further research, according to a study published in Surgery.
“There is an increasing trend of young patients diagnosed with gastric cancer, but without any of the traditional risk factors of gastric cancer. We wanted to find out why we are seeing this and what we might be able to do about it,” Travis E. Grotz, MD, surgical oncologist at Mayo Clinic in Rochester, Minnesota, told Healio.
US based Leap Therapeutics, Inc. a biotechnology company developing targeted immuno-oncology therapeutics, and China headquartered BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, on 3 Jan 2020 announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap’s anti-Dickkopf-1 (DKK1) antibody, in Asia (excluding Japan), Australia, and New Zealand.
Health officials are increasingly concerned about the rise of antibiotic-resistant infections, also known as ‘superbugs’. However, this month an Israel-based pharmaceutical company showed that we may be able to combat this threat.
The FDA granted breakthrough device designation to AI Medical Service’s technology for diagnosing gastric cancer, the company said Monday. The technology uses artificial intelligence to analyze endoscopy images for signs of gastric cancer, a hard-to-diagnose disease associated with a high rate of false negatives. AI Medical Service, which raised $42.9 million last month, is working to bring the technology to the U.S. and its home market of Japan.
Recognizing a need for greater awareness and education around gastric cancer, Taiho Oncology, Inc., today announced its support of four leading gastric cancer advocacy organizations in observance of National Gastric Cancer Awareness Month. The company is sponsoring patient and caregiver programs, education and research throughout 2019 on behalf of Debbie’s Dream Foundation, the Gastric Cancer Foundation, Hope for Stomach Cancer and No Stomach For Cancer®.
Taiho Oncology, Inc. announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase 3 TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine and tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy, were published in the October 10, 2019 issue of JAMA Oncology.